Sergio Traversa - 29 Jan 2024 Form 4 Insider Report for RELMADA THERAPEUTICS, INC. (RLMD)

Role
Chief Executive Officer, Director
Signature
/s/ Sergio Traversa
Issuer symbol
RLMD
Transactions as of
29 Jan 2024
Net transactions value
+$386,738
Form type
4
Filing time
31 Jan 2024, 18:29:27 UTC
Previous filing
19 Dec 2023
Next filing
29 May 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RLMD Common Stock Purchase $117,036 +31,541 +22% $3.71 175,565 29 Jan 2024 Direct F1, F2
transaction RLMD Common Stock Purchase $159,949 +40,999 +23% $3.90 216,564 30 Jan 2024 Direct F1, F3
transaction RLMD Common Stock Purchase $109,752 +27,460 +13% $4.00 244,024 31 Jan 2024 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.
F2 Purchase prices range from $3.69 to $3.75 per share, inclusive.
F3 Purchase prices range from $3.88 to $3.97 per share, inclusive.
F4 Purchase prices range from $3.95 to $4.05 per share, inclusive.